A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2271-2280

  Khalili, Parisa ^a   Arakelian, Ani ^a   Chen, Gaoping ^a   Plunkett, Marian L ^b   Beck, Ivy ^b   Parry, Graham C ^b   Doñate, Fernando ^b   Shaw, David E ^c   Mazar, Andrew P ^b   Rabbani, Shafaat A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b Attenuon LLC   (United States)

^c D E SHAW RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; ASPARTIC ACID; ATN 161; GLYCINE; GREEN FLUORESCENT PROTEIN; INTEGRIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENETIC TRANSFECTION; HEART LEFT VENTRICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; TUMOR VOLUME; WESTERN BLOTTING; X RAY;

ADENOCARCINOMA; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RADIOGRAPHY; SOFT TISSUE NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749577839     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0100     Document Type: Article

References (41)

1. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995;11: 549-99.
2. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R. Integrins in invasive growth. J Clin Invest 2002;109:999-1006.
3. Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU. The breast cancer β4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem 2001;276:25438-46.
4. Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin α4β1 into tumor cells. Am J Pathol 1996;148: 55-61.
5. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am J Pathol 1991;139:767-99.
6. Liapis H, Flath A, Kitazawa S. Integrin αVβ3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996;5:127-35.
7. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem 2000;275:21785-8.
8. Pecheur I, Peyruchaud O, Serre CM, et al. Integrin α(v)β3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
9. Carron CP, Meyer DM, Engleman VW, et al. Peptidomimetic antagonists of αvβ3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 2000; 165:587-98.
10. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;8:991-1006, vii.
11. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 2002;7:3-15.
12. Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-530.
13. Livant DL, Brabec RK, Pienta KJ, et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000;60:309-20.
14. Guo Y-J, Higazi AA-R, Arakelian A, et al. A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 2000;14:1400-10.
15. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 2004;279:31735-44.
16. Doñate F, Guan X, Callahan JA, Mazar AP, Parry GC. ATN-161 (Ac-PHSCN-NH2) has potent anti-angiogenic activity through multiple mechanisms of action and localizes to newly formed blood vessels in vivo. Proc Am Assoc Cancer Res 2005;44:63.
17. Khalili P, Arakelian A, Chen G, Singh G, Rabbani SA. Role of Herceptin in abrogating the progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene 2005;24:6657-66.
18. +-activated chloride channel CLCA2. Cancer Res 1999;59:5488-91.
19. Rabbani SA, Khalili P, Arakelian A, Pizzi H, Chen G, Goltzman D. Regulation of parathyroid hormone related peptide by estradiol (E2): effect of tumor growth and metastasis in vitro and in vivo. Endocrinology 2005;146:2885-94.
20. El Abdaimi K, Dion N, Papavasiliou V, et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 2000;60:4412-8.
21. Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
22. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA. Upregulation of Wnt-1 and β-catenin production in advanced metastatic human prostate cancer: potential pathogenetic and prognostic implications. Cancer 2004;101:1345-56.
23. Wilson JW, Potten CS. The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 2000; 60:4645-53.
24. Byzova TV, Kim W, Midura RJ, Plow EF. Activation of integrin α(V)β(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 2000;254:299-308.
25. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004;64:207-38.
26. Danese S, Sans M, Spencer D, et al. Starving the inflamed gut: angiogenesis blockade as a novel therapeutic approach to experimental colitis. Gastroenterology 2005;128:A40.
27. Winding B, Misander H, Sveigaard C, et al. Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis. J Cancer Res Clin Oncol 2000;126:631-40.
28. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-6.
29. Tani N, Higashiyama S, Kawaguchi N, et al. Expression level of integrin α5 on tumour cells affects the rate of metastasis to the kidney. Br J Cancer 2003;88:327-33.
30. Mould AP, Askari JA, Aota S, et al. Defining the topology of integrin α5β1-fibronectin interactions using inhibitory anti-α5 and anti-β1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the α5 subunit. J Biol Chem 1997;272:17283-92.
31. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000;275:5760-6.
32. Krueger JS, Keshamouni VG, Antanaskova N, Reddy KB. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2001;20:4209-18.
33. Vellon L, Menendez JA, Lupu R. αVβ3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 2005;24:3759-73.
34. Wong NC, Mueller BM, Barbas CF, et al. α-v integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis 1998;16:50-61.
35. Lev DC, Kim LS, Melnikova V, Ruiz M, Ananthaswamy HN, Price JE. Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br J Cancer 2004;91:795-802.
36. Campbell S, Otis M, Cote M, Gallo-Payet N, Payet MD. Connection between integrins and cell activation in rat adrenal glomerulosa cells: a role for Arg-Gly-Asp peptide in the activation of the p42/p44(mapk) pathway and intracellular calcium. Endocrinology 2003;144:1486-95.
37. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 2006;12:2371s-5s.
38. Chelouche-Lev D, Miller CP, Tellez C, Ruiz M, Bar-Eli M, Price JE. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004;40:2509-18.
39. Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003;278:45826-32.
40. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002;38:91-102.
41. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase I trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a β integrin antagonist, in patients with solid tumors. Br J Cancer 2006;94:1621-6.